| Latest Mannkind News Headlines | | Date | Time | Source | | | 06/06/2009 | 11:00AM | PRNUS | Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
Latest data on ultra rapid acting insulin presented at the American Diabetes Association's 69th Scientific Sessions
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder combined... More...>> |
| 06/06/2009 | 11:00AM | PRNUS | AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra... More...>> |
| 04/27/2009 | 9:00AM | PRNUS | MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
VALENCIA, Calif., April 27 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) will release its 2009 first quarter financial results on Monday, May 4, 2009.
Management of the Company will host a conference call to discuss the first quarter financial results and other Company developments at 4:00 PM EDT on... More...>> |
| 03/16/2009 | 2:14PM | PRNUS | MannKind Submits NDA for AFRESA for Treatment of Diabetes
VALENCIA, Calif., March 16 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFRESA(R) (insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA(R) Inhaler... More...>> |
| 03/09/2009 | 6:00AM | PRNUS | MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
VALENCIA, Calif., March 9 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced that it has entered into agreements with Pfizer Inc. (NYSE:PFE) to purchase Pfizer's insulin facility at Industriepark Hoechst, Frankfurt am Main, Germany and assets related to the production of bulk insulin, including... More...>> |
| 02/26/2009 | 7:12PM | PRNUS | MannKind Updates Status of NDA Submission for AFRESA
VALENCIA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today provided an update on the status of its new drug application ("NDA") for AFRESA(R), an ultra rapid-acting insulin that has completed Phase 3 clinical trials. As previously announced, our internal goal was to submit the NDA... More...>> |
| 02/17/2009 | 9:00AM | PRNUS | MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results
- Conference Call to Begin Today at 4:00 PM ET -
VALENCIA, Calif., Feb. 17 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and year ended December 31, 2008.
For the fourth quarter of 2008, total operating expenses were $81.8 million, compared to $79.1... More...>> |
| 02/11/2009 | 4:00PM | PRNUS | MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
VALENCIA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) will release its 2008 fourth quarter financial results on Tuesday, February 17, 2009.
Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments... More...>> |
| 02/02/2009 | 4:00PM | PRNUS | MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
VALENCIA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference on Monday, February... More...>> |
| 01/13/2009 | 4:30PM | PRNUS | MannKind Reports Successful Completion of Device Bioequivalence Trial
VALENCIA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra rapid acting insulin that... More...>> |
| 12/19/2008 | 8:00AM | PRNUS | MannKind to Present at the 27th Annual J.P. Morgan Healthcare Conference
VALENCIA, Calif., Dec. 19 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 PM (PST) at... More...>> |
| 12/18/2008 | 6:00AM | PRNUS | MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
VALENCIA, Calif., Dec. 18 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today released preliminary top-line results from two pivotal Phase 3 clinical studies of AFRESA(TM), the company's ultra rapid acting insulin product (Studies 102 and 030). The protocols for these studies were reviewed and prospectively... More...>> |
| 12/15/2008 | 8:51PM | PRNUS | MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time
VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA(TM), the company's ultra rapid acting, inhaled insulin product, at 9 a.m... More...>> |
| 12/15/2008 | 8:51PM | PRNUS | MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time
VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA(TM), the company's ultra rapid acting, inhaled insulin product, at 9 a.m... More...>> |
| 12/04/2008 | 8:00AM | PRNUS | MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Pivotal efficacy and safety studies meet primary endpoints
VALENCIA, Calif., Dec. 4 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced that it has met the primary endpoints of its final two pivotal Phase 3 studies of AFRESATM, the company's ultra rapid acting, inhaled insulin product. The company... More...>> |
| 11/25/2008 | 5:00PM | PRNUS | MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
VALENCIA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008 at 2:30 PM (EST... More...>> |
| 11/05/2008 | 8:00AM | PRNUS | MannKind Corporation Reports Third Quarter Financial Results
- Conference Call Today at 9:00 a.m. EST -
VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the third quarter ended September 30, 2008.
For the third quarter of 2008, total operating expenses were $69.1 million, compared to $75.6 million for... More...>> |
| 11/03/2008 | 5:00PM | PRNUS | MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
VALENCIA, Calif., Nov. 3 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, November 10, 2008 at 9:55 AM (EST... More...>> |
| 10/29/2008 | 7:54PM | PRNUS | MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
VALENCIA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) will release its 2008 third quarter financial results on Wednesday, November 5, 2008 at 8:00 a.m. EST.
Management of the Company will host a conference call to discuss the third quarter financial results, clinical progress and other... More...>> |
| 09/17/2008 | 12:00PM | PRNUS | MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
DANBURY, Conn., Sept. 17 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced that it has proposed to the United States Food and Drug Administration to use AFRESA as the trade name for its Technosphere Insulin System.
AFRESA (pronounced uh-FRESS-uh) was unveiled today by Alfred Mann, Chairman... More...>> |
|